Program—Tuesday, July 25
Ask an Expert breakfast session
Want to learn more about careers in the STD field? To know the secrets to academic promotion? How to use social media in your professional life? Now is your chance to Ask an Expert! ASTDA is proud to sponsor the Ask an Expert breakfast session at the 2023 STI/HIV World Congress on Tuesday, July 25th from 7:00-8:00 am CT. During the session, you will have the opportunity to participate in a small group, informal discussion with an expert in our field around a specific topic. To ensure the ability to have meaningful discussions, space is limited and registration is required with preference given to participants early in their career (i.e., not more than seven years from completion of training). If you are interested in participating, please complete this registration form: https://www.surveymonkey.com/r/ASTDABreakfastRegistration
Plenary Talks
- PL1.1 How can we regain trust in science?– Jeff Klausner
- PL1.2 Gender, health inequality and reproductive rights – Sarah Hawkes
- PL2.1 Putting Pleasure back into Sexual Health – Keosha Bond & Sandrine Attalah
Spotlight: Innovations in STI Care
Organizer: Emma Harding-Esch
Moderators: Catherine Mathews and Emma Harding-Esch
- SP1.1 How to maximize potential of point-of-care tests & decentralized testing – Teodora Wi
- SP1.2 How much can automated care replace clinicians? – Claudia Estcourt
- SP1.3 Social innovation and STI care – Joe Tucker
- Panel Discussion
Spotlight: STI Guidelines
Moderators: Claire Dewsap and Laura Bachman
- SP2.1 Why are there differences in our guidelines? –Kim Workowski
- SP2.2 Addressing trans and non-binary health in guidelines – Asa Radix
- SP2.3 Living guidelines – what does good look like – Jackie Sherrard
- Panel Discussion
Symposium: Tackling Stigma, Strengthening Communities
Organizer: Adele Benzaken
Moderators: Adele Benzaken and Jacky Jennings
- SY1.1 STIs – the risk of stigmatising stigma – Jorge Saavedra, AHF
- SY1.2 Decriminalisation of same-sex relations and social attitudes- Rayner Tan
- SY1.3 The Longest Mile: Stigma’s impact on sexual health for women in the Southern US – Latesha Elopre
Symposium: Worldwide strategies against antimicrobial resistance
Organizer: Magnus Unemo
Moderators: Tania Crucitti and Magnus Unemo
- SY2.1 STI treatment options are running out – Magnus Unemo
- SY2.2 Molecular resistance testing and resistance-guided STI therapy: when and how to use – Catriona Bradshaw
- SY2.3 Future treatments for STIs – Lindley Barbee
- SY2.4 Doxycycline PrEP and PEP – impact on microbiome and antimicrobial resistance – Fabian Kong
- SY2.5 Optimizing STI treatment using pharmacodynamics – Magnus Unemo
Symposium: Vaccines for STI prevention: development, acceptance and equity
Moderators: Caroline Cameron and Anna Wald
- SY3.1 State of syphilis vaccine development – Lorenzo Giacani
- SY3.2 State of vaccine development for Neisseria gonorrhoeae – Sanjay Ram
- SY3.3 State of chlamydia vaccine development – Alvaro Borges
- SY3.4 STI vaccine acceptance and equity – Alison Footman
Symposium: Queer Theory and Intersectionality in STI prevention and care
Moderators: Bradly Stoner and Jackson Montgomery
- SY4.1 Centering Sex Positivity in STI & HIV prevention – Ruth Morgan Thomas
- SY4.2 Community-Led Responses: Vital for Effective STI Interventions, Policy and Impact– Solange Baptiste
- SY4.3 Chemsex & Sexualised Drug Use – Glenn-Milo Santos
- SY4.4 Trans and Non-Binary Sexual Health – Olivia Van Gerwen
Oral Session: Vaginal Conditions
Moderators: Janneka Van de Wijgert and Hillary Reno
- O1.1 Bacterial Vaginosis and Spontaneous Clearance of Urogenital Chlamydia trachomatis in the Longitudinal Study of Vaginal Flora – Sarah Brown
- O1.2 The contribution of the vaginal microbiota to treatment failure following first-line antibiotics for bacterial vaginosis – Erica Plummer
- O1.3 Increasing rates of non-albicans Candida species and fluconazole resistant Candida albicans in women with recurrent vulvovaginal candidiasis in a UK region – Jennifer Ratner
- O1.4 Sexual transmission of urogenital bacteria in heterosexual partners: whole metagenome sequencing evidence from a sexual network study – Kayla Carter
- O1.5 Secreted Proteases from Bacterial Vaginosis-Associated Bacteria Target Human MMP-8 and Modulate Endocervical Barrier Function – Karen Lithgow
- O1.6 Spontaneous resolution and treatment outcomes in men with Trichomonas vaginalis infection – Christina Muzny
Oral Session: Key Populations - 1: Reaching the Vulnerable
Moderators: Abby Turner Norris and Aneeka Ratnyake
- O2.1 Calculating the value of behavioural science and community engagement in promoting vaccination of MSM: a transmission-dynamic health-economic analysis of 4CMenB (Bexsero) vs gonorrhoea as an example – Peter White
- O2.2 Relationships and risk: A mixed-methods study of perceptions and management of STI/HIV risk among heterosexual-identifying men who have sex with both men and women – Tyrone Curtis
- O2.3 “It’s not safe for me and what would it achieve?” Acceptability of patient referral partner notification for sexually transmitted infections to adolescents and young people in Zimbabwe – Chido Dziva Chikwari
- O2.4 Preparedness of pregnant women to wait for same-day results of sexually transmitted infections – Ranjana Gigi
- O2.5 Mixed methods analysis of network structures, support exchanged, and communication patterns within the social networks of transgender women in Lima, Peru 0.2.5 – Rayner Kay Jin Tan
- O2.6 Community-based integrated HIV and sexual and reproductive health services: why did we miss young men and what is it going to take to reach them? – Constancia Mavodza
Oral Session: Syphilis: Epidemiology and Clinical
Moderators: Jane Rowley & Susan Tuddenham
- O3.1 Evaluating the clinical features of reported breakthrough cases of congenital syphilis — United States, 2016–2020 – Kevin O’Callaghan
- O3.2 Rates of reported primary and secondary syphilis among men who have sex with men compared to men who have sex with women only and women who have sex with men in 37 US states, 2018 – Jeremy Grey
- O3.3 Detection of Treponema pallidum at asymptomatic oral, anal and vaginal sites in men and women reporting contact with syphilis. – Ei Aung
- O3.4 Evolutionary insights into syphilis epidemiology – applying Treponema pallidum genomics in high- and low-income settings- Mathew Beale
- O3.5 Temporal Trends in HIV Status by Race/Ethnicity Among Reported Primary and Secondary Syphilis Cases Among Gay, Bisexual, and Other Men who have sex with Men — United States, 2011–2020 – Sarah Wondmeneh
- O3.6 Rapid Plasma Reagin (RPR) sero-reversion after treatment and its association with Prior Treponema Pallidum infection: analysis from the PICASSO cohort among people with early syphilis in Peru –Michael Reyes-Diaz
Oral Session: Optimizing urethritis treatment – M. genitalium and pathogens of idiopathic urethritis
Moderators: Teresa Batteiger and Jorgen Jensen
- O4.1 Exploring current etiologies of urethritis: associations of urethral microorganisms and urethritis among men attending 6 STD clinics in the US, 2017-2018 – Emily Learner
- O4.2 gyrA mutations in Mycoplasma genitalium contribute to moxifloxacin failure – a new target for resistance-guided therapy – Gerald Murray
- O4.3 MgSeq: Enabling M. genitalium identification and antimicrobial resistance detection in genital and extra-genital samples from female sex workers in Ecuador using multiplex PCR and nanopore sequencing – Claire Broad
- O4.4 Mycoplasma genitalium Surveillance Data from 2020-2022: Results from the Mycoplasma genitalium in the US (MyGeniUS) Project – Lisa Manhart
- O4.5 Efficacy of minocycline for the treatment of Mycoplasma genitalium – Lenka A. Vodstrcil
- O4.6 Idiopathic nongonococcal urethritis may be due to emerging and spontaneously cleared pathogens – David Nelson
Oral Session: HIV PrEP, Viral STIs
Moderators: Bill Miller and Charlie Peterson
- O5.1 PrEP Method Preferences and Anticipated Stigma Among Female, Male, and Transgender Sex Workers in India – Anne Fehrenbacher
- O5.2 THE ACCEPTABILITY OF PHARMACY-DELIVERED PREP IN KENYA: PROVIDER AND CLIENT PERCEPTIONS – Magdaline Asewe
- O5.3 Concordance between self-reported PrEP use using a diary app and intracellular tenofovir diphosphate in the Amsterdam PrEP demonstration project – Eline Wijstma
- O5.4 Age patterns of HSV-2 incidence and prevalence in two communities in Rakai, Uganda: a catalytic incidence model applied to population-based seroprevalence data – Lilith Whittles
- O5.5 Pritelivir for the treatment of resistant HSV infections in immunocompromised patients: update on an ongoing Phase 3 trial and Early Access Program – Alexander Birkmann
- O5.6 Knowledge and acceptability of Human Papillomavirus vaccination for young adult women in rural Mysore District, India: a qualitative study – Kate Coursey
Oral Session: Biomedical prevention for STIs and HIV
Moderators: Marc Steben and Sebastion Fuller
- O6.1 High uptake of Doxycycline for STI prevention (doxy-PEP) among individuals using HIV PrEP at a municipal sexual health clinic in San Francisco, California – Oliver Bacon
- O6.2 Syphilis testing, incidence, and reinfection among gay and bisexual men with and without HIV in Australia over a decade spanning HIV PrEP implementation – Michael Traeger
- O6.3 Self-reported adherence to event-driven doxycycline postexposure prophylaxis for sexually transmitted infection prevention among cisgender women – Jenell Stewart
- O6.4 A genomic perspective on the near-term impact of doxycycline post-exposure prophylaxis on Neisseria gonorrhoeae antimicrobial resistance – Tatum Mortimer
- O6.5 Discontinuation of Pre-Exposure Prophylaxis and associated factors among Female Commercial Sex Workers attending the most at-risk population clinic, Mulago Hospital, Uganda – Racheal Naturinda
- O6.6 PrEP outcomes and sexual health in China during COVID-19 lockdowns – Chunyan Li
Late Breaker Oral Session 1: LGV, chlamydia and mpox
Moderators: Nicola Low and Kate Seib
- LB1.1 Prevalence and epidemiology of Lymphogranuloma venereum in France, 2020-2022- Cecile Bebear
- LB1.2 Genetic diversity of Chlamydia trachomatis infection among patients presenting with genital lesions in Malawi – Christopher Hennelly
- LB1.3 Evaluating immunological responses of mRNA-based Chlamydia vaccines – Wei He
- LB1.4 Mpox resurgence in 2023 in Toronto, Canada – surveillance and vaccine approaches – Sylvia Ota
- LB1.5 Modeling the impact of vaccination and sexual behavior adaptation on reported cases of mpox in Washington D.C. – Patrick Clay
- LB1.6 Modeling potential mpox resurgence among gay, bisexual, and other men who have sex with men in Washington, DC. – Emily Pollock
Social Contact